AU2001282874A1 - Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) - Google Patents

Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)

Info

Publication number
AU2001282874A1
AU2001282874A1 AU2001282874A AU8287401A AU2001282874A1 AU 2001282874 A1 AU2001282874 A1 AU 2001282874A1 AU 2001282874 A AU2001282874 A AU 2001282874A AU 8287401 A AU8287401 A AU 8287401A AU 2001282874 A1 AU2001282874 A1 AU 2001282874A1
Authority
AU
Australia
Prior art keywords
quinuclidine
disease
treatment
substituted aryl
acetylcholine receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001282874A
Inventor
Vincent E. Groppi Jr.
Jason K. Myers
David W. Piotrowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of AU2001282874A1 publication Critical patent/AU2001282874A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AU2001282874A 2000-08-18 2001-08-17 Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) Abandoned AU2001282874A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US22616400P 2000-08-18 2000-08-18
US60226164 2000-08-18
US60/226,164 2000-08-18
US28496601P 2001-04-19 2001-04-19
US60/284,966 2001-04-19
US60284966 2001-04-19
PCT/US2001/021138 WO2002016358A2 (en) 2000-08-18 2001-08-17 Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)

Publications (1)

Publication Number Publication Date
AU2001282874A1 true AU2001282874A1 (en) 2002-03-04

Family

ID=26920268

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001282874A Abandoned AU2001282874A1 (en) 2000-08-18 2001-08-17 Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)

Country Status (6)

Country Link
US (1) US6479510B2 (en)
EP (1) EP1381603A2 (en)
JP (1) JP2004506735A (en)
AU (1) AU2001282874A1 (en)
PE (1) PE20030226A1 (en)
WO (1) WO2002016358A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SE0000540D0 (en) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
GB0010955D0 (en) * 2000-05-05 2000-06-28 Novartis Ag Organic compounds
WO2003018585A1 (en) * 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
NZ531786A (en) 2001-10-02 2006-10-27 Upjohn Co Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
EP1453828A2 (en) * 2001-10-16 2004-09-08 AstraZeneca AB Azabicyclic compounds for the treatment of fibromyalgia syndrome
NZ554913A (en) 2001-12-14 2009-01-31 Targacept Inc Methods and compositions for the treatment of central nervous system disorders
DE10164139A1 (en) 2001-12-27 2003-07-10 Bayer Ag 2-heteroaryl carboxamides
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
EP2062595A1 (en) * 2002-12-06 2009-05-27 The Feinstein Institute for Medical Research Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
WO2004052889A1 (en) * 2002-12-06 2004-06-24 Pharmacia & Upjohn Company Llc Compounds as radioligands for the diagnosis of disease
ES2356356T3 (en) 2003-10-15 2011-04-07 Targacept, Inc. AZABICYCLIC COMPOUNDS TO RELIEF PAIN AND TREAT THE DISORDERS OF THE CENTRAL NERVOUS SYSTEM.
WO2005046603A2 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
US20050137398A1 (en) * 2003-12-22 2005-06-23 Jianguo Ji 3-Quinuclidinyl heteroatom bridged biaryl derivatives
PE20060437A1 (en) 2004-06-18 2006-06-08 Novartis Ag AZA-BICYCLONONE COMPOUNDS AS CHOLINERGIC LINKS OF nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
ZA200700811B (en) 2004-08-06 2008-10-29 Otsuka Pharma Co Ltd Aromatic compound
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
ATE482959T1 (en) 2005-08-22 2010-10-15 Targacept Inc HETEROARYL-SUBSTITUTED DIAZATRICYCLOALKANES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
US8236826B2 (en) 2005-12-05 2012-08-07 Otsuka Pharmaceutical Co., Ltd. Diarylether derivatives as antitumor agents
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
WO2007071358A1 (en) * 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
UA95978C2 (en) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Stat3/5 activation inhibitor
SA08290475B1 (en) 2007-08-02 2013-06-22 Targacept Inc (2S,3R)-N-(2-((3-Pyridinyl)Methyl)-1-Azabicyclo[2.2.2]Oct-3-yl)Benzofuran-2-Carboxamide, Novel Salt forms, and Methods of Use Thereof
CA2701126A1 (en) 2007-10-01 2009-04-09 Comentis, Inc. 4-substituted quinuclidine derivatives, methods of production, and pharmaceutical uses thereof
RS52941B (en) 2008-02-13 2014-02-28 Targacept Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
PT2540297E (en) 2008-11-19 2015-08-26 Forum Pharmaceuticals Inc Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
AU2010247835A1 (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
JO3078B1 (en) * 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv Morpholinothiazoles as alpha 7 positive allosteric modulators
SA111320455B1 (en) 2010-05-17 2014-10-16 Envivo Pharmaceuticals Inc Acrystalline form of (R)-7-chloro-N-(quinuclidin-3-‎Yl)benzo[B]thiophene-2-carboxamide hydrochloride ‎monohydrate
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit
WO2016007630A1 (en) 2014-07-11 2016-01-14 Alpharmagen, Llc Quinuclidine compounds for modulating alpha7 -nicotinic acetylcholine receptor activity
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3702324A (en) 1970-06-24 1972-11-07 Stanford Research Inst 3,4,5-trimethoxybenzamides of substituted anilines and of alkylpiperidines
FI763021A (en) 1975-11-03 1977-05-04 Thomae Gmbh Dr K
FI74707C (en) 1982-06-29 1988-03-10 Sandoz Ag FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA ALKYLENOEVERBRYGGADE PIPERIDYLESTRAR ELLER -AMIDER AV BICYKLISKA KARBOXYLSYROR.
FR2529548A1 (en) 1982-07-02 1984-01-06 Delalande Sa NOVEL DERIVATIVES OF AMINO-3 QUINUCLIDINE, THEIR PROCESS AND THEIR THERAPEUTIC APPLICATION
US5175173A (en) 1983-12-22 1992-12-29 Sun Jung Hui Carboxamides useful as antiemetic or antipsychotic agents
US4593034A (en) 1984-04-06 1986-06-03 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides
US4820715A (en) 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
US4870181A (en) 1985-02-04 1989-09-26 A. H. Robins Company, Incorporated Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2])octan-3-yl)aminobenzamides
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE3688296T2 (en) 1985-03-14 1993-11-04 Beecham Group Plc MEDICINES FOR TREATING EMERGENCY.
GB8520616D0 (en) 1985-08-16 1985-09-25 Beecham Group Plc Compounds
US4717563A (en) 1986-03-05 1988-01-05 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs
HU202108B (en) 1986-07-30 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
DE3780276T2 (en) 1986-12-16 1993-02-25 Robins Co Inc A H NON-RELAXING N- (1-AZABICYCLO (2.2.2) OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES.
US5237066A (en) * 1987-02-04 1993-08-17 Delande S.A. Enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their application in therapy
US4835162A (en) 1987-02-12 1989-05-30 Abood Leo G Agonists and antagonists to nicotine as smoking deterents
DE3822792C2 (en) 1987-07-11 1997-11-27 Sandoz Ag New use of 5HT¶3¶ antagonists
GB8718345D0 (en) 1987-08-03 1987-09-09 Fordonal Sa N-substituted benzamides
GB8720805D0 (en) 1987-09-04 1987-10-14 Naylor R J 2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides
US4921982A (en) 1988-07-21 1990-05-01 Eli Lilly And Company 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists
US5206246A (en) 1987-10-16 1993-04-27 A. H. Robins Company, Incorporated Anxiolytic-R-n(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides
IE62231B1 (en) 1987-12-24 1995-01-11 Wyeth John & Brother Ltd Heterocyclic compounds
FR2625678B1 (en) 1988-01-13 1991-06-07 Delalande Sa ANOREXIGENAL AGENTS BASED ON N- (QUINUCLIDIN-3-YL) -BENZAMIDES OR THIOBENZAMIDES
US4863919A (en) * 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
DE3810552A1 (en) 1988-03-29 1989-10-19 Sandoz Ag Esters and amides of indole-, benzo[b]thiophene or benzo[b]furancarboxylic acids or 4-amino-2-methoxybenzoic acids with N-heterocyclic or N-heterobicyclic alcohols or amines, processes for their preparation, pharmaceutical compositions containing them and applicator for administration thereof
US5246942A (en) 1988-04-27 1993-09-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Pharmaceutically useful dibenzofurancarboxamides of specific stereo-configuration
EP0353372B1 (en) 1988-08-04 1993-02-03 Synthelabo Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides
EP0353371A1 (en) 1988-08-04 1990-02-07 Synthelabo Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
AU5650890A (en) 1989-05-24 1990-12-18 Nippon Shinyaku Co. Ltd. Indole derivatives and medicine
US5290938A (en) 1989-09-15 1994-03-01 Chiron Laboratories A.S. Preparation of S-(-)- and R-(+)-N-(quinuclidinyl-3)-amide
EP0436245A1 (en) 1989-12-27 1991-07-10 Duphar International Research B.V Substituted 3,4-annelated benzimidazol-2(1H)-ones
US5057519A (en) 1990-06-11 1991-10-15 Bristol-Myers Squibb Company 5-HT3 antagonists: use in reducing opiate tolerance
US5070095A (en) 1990-12-12 1991-12-03 A. H. Robins Company, Incorporated Substituted 4-(amidino)benzamides of 1-azabicyclo[2.2.2]octan-3- and -4-amine as gastric prokinetic, antiemetic, and anxiolytic agents
GB9027487D0 (en) 1990-12-19 1991-02-06 Beecham Group Plc Pharmaceuticals
US5084460A (en) 1990-12-24 1992-01-28 A. H. Robins Company, Incorporated Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
JPH06506467A (en) 1991-03-08 1994-07-21 ローヌ−プーラン　ローラー　インターナショナル（ホウルディングス）　インコーポレイテッド Polycyclic tertiary amine polyaromatic squalene synthetase inhibitor
US5491148A (en) 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
DE4115215A1 (en) 1991-05-10 1992-11-12 Merck Patent Gmbh INDOLDER DERIVATIVES
US5236931A (en) 1992-03-26 1993-08-17 A. H. Robins Company, Incorporated 2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol
US5273972A (en) 1992-03-26 1993-12-28 A. H. Robins Company, Incorporated [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
ATE279516T1 (en) 1993-03-08 2004-10-15 Merck & Co Inc HUMAN NEURONAL NICOTINE-ACETYLCHOLINE RECEPTOR COMPOUNDS AND METHODS OF THEIR USE
IL109451A0 (en) 1993-04-29 1994-07-31 Zeneca Ltd Heterocyclic derivatives
US5723103A (en) 1994-12-09 1998-03-03 Vanderbilt University Substituted benzamides and radioligand analogs and methods of use
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
SE9600683D0 (en) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
JP2003501022A (en) 1999-05-27 2003-01-14 ファルマシア・アンド・アップジョン・カンパニー Method for measuring ion channel conductance and composition thereof
SE9903760D0 (en) * 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (en) * 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (en) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
EP1381603A2 (en) 2004-01-21
JP2004506735A (en) 2004-03-04
WO2002016358A2 (en) 2002-02-28
PE20030226A1 (en) 2003-03-14
WO2002016358A3 (en) 2002-07-18
US20020049225A1 (en) 2002-04-25
US6479510B2 (en) 2002-11-12

Similar Documents

Publication Publication Date Title
AU2001282874A1 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
AU2001282910A1 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
AU2001282875A1 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001284646A1 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282873A1 (en) Quinuclidine-substituted aryl compounds for treatment of disease
AU2001284645A1 (en) Quinuclidine-substituted aryl compounds for treatment of disease
AU1294401A (en) Methods for treating fibroproliferative diseases
PL357634A1 (en) Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
AU2001233299A1 (en) Methods for treating alzheimer's disease
AU2002303283A1 (en) Methods for treating drug addiction
AU1246101A (en) Set for blood processing
ZA200203252B (en) Process for preparing 4"-substituted-9-deoxo-9A-AZA-9A-homoerythromycina derivatives.
EE200100536A (en) Process for the preparation of amine-platinum complexes
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
AU6932000A (en) Tacrine derivatives for treating alzheimer's disease
AU5319700A (en) Nicotine receptor ligands
AU2000265525A1 (en) Medicament for treating intestinal diseases
AU8322401A (en) Indole compounds useful for the treatment of cancer
AUPQ232599A0 (en) Drug for treating fractures
AU7040700A (en) Process for preparing sulfoxide compounds
AU7636800A (en) Improved ricin-like toxins for treatment of cancer
AUPP870999A0 (en) Method of treatment of equine disease
AU2001250866A1 (en) Treatment for benign positional vertigo
EP1325751A4 (en) Novel drugs for liver diseases
AU2001254550A1 (en) Radiometal complexes of 2-pyrrolylthiones for imaging a therapy